Skip to main content
Journal of the Egyptian National Cancer Institute

Table 3 Characteristics of 3 cases achieved pCR after neoadjuvant chemotherapy

From: The conundrum of metaplastic breast cancer: a single Egyptian institution retrospective 10-year experience (2011–2020)

Case no.

Age (y)

Metaplastic subtype

Grade

Molecular subtype

NACT regimen

PORT

DFS (ms)

OS (ms)

1

55

SCC

III

LB-HER2+

TCH × 6

Yes

12.63

25.72

2

56

SCC

III

TN

AC × 4-Tw × 12

Yes

17.8

25.3

3

35

SCC

III

TN

FAC × 4-Tax/Carb × 4

Yes

46.88

56.09

  1. AC adriamycin and cyclophosphamide, FAC fluorouracil, adriamycin, and cyclophosphamide, LB-HER2+ luminal B with HER2 overexpression, ms months, NACT neoadjuvant chemotherapy, PORT postoperative radiation therapy, SCC squamous cell carcinoma, Tax/Carb taxol and carboplatin, TCH docetaxel, carboplatin, and trastuzumab, TN triple negative, Tw taxol weekly, y year
Back to article page